Molecule-targeted agents in endometrial cancer

Current Opinion in Oncology

Volumn 20, Issue 5, 2008, Pages 554-559

  Delmonte, Angelo ^a   Sessa, Cristiana ^a,b  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

Endometrial cancer; Human epidermal growth factor receptor 2; Mammalian target of rapamycin inhibitors; Phosphatase and tensin homologue deleted on chromosome 10; Trastuzumab

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; DEFOROLIMUS; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; INITIATION FACTOR 4E BINDING PROTEIN 1; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAPAMYCIN; RAPAMYCIN DERIVATIVE; S6 KINASE; TEMSIROLIMUS; TRASTUZUMAB; ANTINEOPLASTIC AGENT; PROTEIN KINASE;

ACNE; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER STAGING; CARCINOGENESIS; CARCINOSARCOMA; CELL PROLIFERATION; CHROMOSOME 10; CLEAR CELL CARCINOMA; CLEAR CELL SARCOMA; CLINICAL TRIAL; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; GASTROINTESTINAL SYMPTOM; GENE ACTIVATION; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HYPERLIPIDEMIA; LOADING DRUG DOSE; MACULOPAPULAR RASH; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; REVIEW; STOMATITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ENDOMETRIUM TUMOR; FEMALE; METABOLISM; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 59649096025     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32830b0deb     Document Type: Review

References (57)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
2. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet 2005; 366:491-505.
3. Fleming GF. Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol 2007; 25:2983-2990. This recent article highlights in a complete manner the current state of the art in the management of endometrial cancer.
4. Aapro MS, van Wijk FH, Bolis G, et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 2003; 14:441-448.
5. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial doxorubicin plus cisplatin with or without paclitaxel plus filgastrim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004; 22:2159-2166.
6. Shang Y. Molecular mechanism of oestrogen and SERMs in endometrial carcinogenesis. Nature 2006; 6:360-368.
7. Hecht JL, Mutter GL Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006; 24:4783-4791.
8. Liu FS. Molecular carcinogenesis of endometrial cancer. Taiwan J Obstet Gynecol 2007; 46:26-32.
9. Mutter GL, Boynton KA, Faquin WC, et al. Allelotype mapping of unstable microsatellites establishes direct lineage continuity between endometrial precancers and cancer. Cancer Res 1996; 56:4483-4486.
10. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000; 92:924-930.
11. Lax SF, Kendall B, Tashiro H, et al. The frequency of p53, K-ras mutations and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000; 88:814-824.
12. Fukuchi T, Sakamoto M, Tsuda H, et al. Beta-catenin mutations in carcinoma of the uterine endometrium. Cancer Res 1998; 58:3526-3528.
13. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296:1655-1657.
14. Franke TF, Kaplan DR, Cantley LC, et al. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 1997; 275:665-668.
15. Stokoe D, Stephens LR, Copeland T, et al. Dual role of phosphatidylinositol-3,4,5-triphosphate in the activation of protein kinase B. Science 1997; 277:567-570.
16. Stephens L, Anderson K, Stokoe D, et al. Protein kinase B kinases that mediate phosphatidylinositol-3,4,5-triphosphate-dependent activation of protein kinase B. Science 1998; 279:710-714.
17. Martin DE, Hall MN. The expanding TOR signalling network. Curr Opin Cell Biol 2005; 17:158-166.
18. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphory-latesthelipid second messenger phosphatidylinositol-3,4,5- triphosphate. J Biol Chem 1998; 273:13375-13378.
19. Stambolic V, Tsao MS, Macpherson D, et al. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten +/-mice. Cancer Res 2000; 60:3605-3611.
20. Oda K, Stokoe D, Taketani Y, et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005; 65:10669-10673.
21. Kong D, Suzuki A, Zou TT, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 1997; 17:143-144.
22. Swisher EM, Peiffer-Schneider S, Mutch DG, et al. Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability. Cancer 1999; 85:119-126.
23. Sasaki H, Nishi H, Takhashi H, et al. Mutation of the Ki-ras proto-oncogene in human endometrial hyperplasia and carcinoma. Cancer Res 1993; 53:1906-1910.
24. Dinulescu DM, Ince TA, Quade BJ, et al. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005; 11:63-70.
25. Tang XM, Rossi MJ, Masterson BJ, et al. Insuline-like growth factor I (IGFI), IGFI receptors, and IGF binding proteins 1-4 in human uterine tissue: tissue localization and IGFI action in endometrial stromal and myometrial smooth muscle cells in vitro. Biol Reprod 1994; 50:1113-1125.
26. Lee YR, Park J, Yu HN, et al. Up-regulation of PI3K/Akt signaling by 17beta-estradiol through activation of estrogen receptor-alfa, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells. Biochem Biophys Res Commun 2005; 336:1221-1226.
27. McCampbell AS, Broaddus RR, Loose DS, et al. Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res 2006; 12:6373-6378.
28. Brader S, Eccles SA. Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 2004; 90:2-8.
29. Tanno S, Mitsuuchi Y, Altomare DA, et al. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res 2001;61:589-593.
30. Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998; 391:184-187.
31. Alessi DR, Sakamoto K, Bayascas JR. Lkb1-dependent signaling pathways. Annu Rev Biochem 2006; 75:137-163.
32. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115:577-590.
33. Contreras CM, Gurumurthy S, Hayine JM, et al. Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Res 2008; 68:759-766.
34. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995; 26:1268-1274.
35. Goodfellow P, Buttin B, Herzog T, et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A 2003; 100:5908-5913.
36. Sherman ME, Bitterman P, Rosenhein NB, et al. Uterine serous carcinoma. A morhpologically diverse neoplasm with unifying clinicopathological features. Am J Pathol 1992; 16:600-610.
37. Santin AD. HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed? Gynecol Oncol 2003; 88:263-265.
38. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast cancer and ovarian cancer. Science 1989; 244:707-712.
39. Graus-Porta D, Beerli RR, Daly JM, et al. ErbB-2, the preferred heterodimer-ization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997; 16:1647-1655.
40. Busse D, Doughty RS, Arteaga CL HER-2/neu (erbB-2) and the cell cycle. Semin Oncol 2000; 27 (Suppl 11):3-8.
41. Santin AD, Bellone S, Gokden M, et al. Overexpression of HER-2/neu in uterine papillary serous carcinoma. Clin Cancer Res 2002; 8:1271-1279.
42. Coronado PJ, Vidart JA, Lopez-Asenjo JA, et al. p53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression. Eur J Obstet Gynecol Reprod Biol 2001; 98:103-108.
43. Slomovitz BM, Broaddus RR, Burke TW, et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 2004; 22:3126-3132.
44. Slomovitz BM, Wu W, Broaddus RR, et al. mTOR inhibition is a rational target for the treatment of endometrial cancer. Proc Am Soc Clin Oncol 2004; 22 [abstract 5076].
45. Lee VW, Chapman JR. Sirolimus: its role in nephrology. Nephrology 2005; 10:606-614.
46. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352:1317-1323.
47. Oza AM, Elit L, Biagi J, et al. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer: NCIC IND 160. Proc Am Soc Clin Oncol 2006; 24 [abstract 3003].
48. Colombo N, McMeekin P, Schwartz J, et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. Proc Am Soc Clin Oncol 2007; 25 [abstract 5516].
49. Slomovitz B, Burke T, Lu K, et al. Loss of PTEN expression associated with response to RAD001 (mTOR inhibitor) in patients with recurrent endometrial cancer: translational evaluation from a phase II study. In: 38th annual meeting on women's cancer; 2007 [abstract 62].
50. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 12:2336-2347.
51. Rivera VM, Kreisberg J, Mita M, et al. Pharmacodynamic study of skin biopsy specimens in patients with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor. J Clin Oncol 2005; 23:200s [abstract 3033].
52. O'Reilly TM, Wood JM, Littlewood-Evans A, et al. Differential antivascular effects of mTOR or VEGF pathway inhibition: a rational basis for combining RAD001 and PTK787/ZK222584. In: Proceedings of the American Association for Cancer Research; 16-20 April 2005; California, USA; 2005 [abstract 3038].
53. Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005; 120:747-759.
54. Eisen HJ, Tuycu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant-recipients. N Engl J Med 2003; 349:847-858.
55. Lorber Ml, Mulgaonkar S, Butt KM, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005; 80:244-252.
56. Santin AD, Zhan F, Bellone S, et al. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol 2005; 192:813-818.
57. Villella JA, Cohen S, Hibshoosh H, et al. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer 2006; 16:1897-1902.